DECONGESS L CAP

11.00 EGP

Out of stock

DECONGESS L CAP

pseudoephedrine, loratadine, respiratory tract agents.

DECONGESS L CAP

ACTIVE-INGREDIENT

INDICATION

DOSAGE

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box.

ACTIONS:

Loratadine is a potent long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonistic activity. Pseudoephedrine hydrochloride, one of the naturally occurring alkaloids of Ephedra and an orally administered vasoconstrictor, produces a gradual but sustained decongestant effect facilitating shrinkage of congested mucosa in upper respiratory areas. The mucosa membrane of the respiratory tract is decongested through the action on the sympathetic nerves.

INDICATIONS AND USAGE:

Decongess-L capsules are indicated for the relief of symptoms associated with allergic rhinitis and the common cold Including nasal congestion, sneezing, rhinorhea, pruritus and lacrimation. Decongess-L capsules are recommended when both the antihistaminic properties of loratadine and the decongestant effect of pseudoephedrine hydrochloride are desired.

DOSAGE AND ADMINISTRATION:

Adults and Children 12 years of age and over: One Decongess-L capsules twice a day

DRUG INTERACTIONS:

When administered concomitantly with alcohol, loratadine has no potentiating effect as measured by psychomotor performance studies.

Increase in plasma concentrations of loratadine have been reported after concomitant use with ketoconazole, erythromycin or cimetidine in controlled clinical trials, but without clinically significant changes (including electrocardiographic).

Other drugs known to inhibit hepatic metabolism should be coadministered with caution until definitive interaction studies can be completed.

When sympathomimetics are given to patients receiving monoamine oxidase (MAO) inhibitors, hypertensive reactions, including hypertensive crises may occur. The antihypertensive effects of methyldopa mecamylamine, reserpine and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacitds increase the rate of pseudoephedrine absorption; kaolin decreases it.

Drug/Laboratory Test Interactions: Antihistamines should be discontinued approximately 48 hours prior to skin testing procedures since these drugs may prevent or diminish otherwise positive reactions to dermal reactivity indicators. The in vitro addition of pseudoephedrine to sera containing the cardiac isoenzyme MB of serum creatine phosphokinase progressively inhibits the activity of the enzyme. The inhibition becomes complete over six hours.During the marketing of loratadine, alopecia, anaphylaxis, and abnormal hepatic function have been reported rarely.

PRECAUTIONS:

Patient 60 year of age are more likely to have adverse reactions to sympathomimetics amines (such as pseudoephedrine).

Consequently, caution should be exercised when administering a repeat action formulation to elderly patients. Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; an initial dose of one capsule daily is recommended.

PACK OF DECONGESS L CAP

DECONGESS L CAP MANUFACTURED BY

https://www.webmd.com/drugs/2/drug-2625-6204/loratadine-pseudoephedrine-oral/loratadine-pseudoephedrine-sustained-release-oral/details

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Be the first to review “DECONGESS L CAP”

Your email address will not be published.

Shopping Cart
Don`t copy text!
Scroll to Top